RT Journal Article
SR Electronic
T1 Evidence underlying the clinical management of diabetic macular oedema
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP 353
OP 357
DO 10.7861/clinmedicine.13-4-353
VO 13
IS 4
A1 Michael Andrew Williams
A1 Usha Chakravarthy
YR 2013
UL http://www.rcpjournals.org/content/13/4/353.abstract
AB Diabetic retinopathy (DR) is the leading cause of visual loss in the developed world in those of working age, and its prevalence is predicted to double by 2025. The management of diabetic retinopathy has traditionally relied on screening, on laser treatment delivered by ophthalmologists, and on optimising blood glucose and blood pressure. Recent evidence suggests that the role of systemic factors is more complex than originally thought, and that drugs such as ACE inhibitors, fibrates and glitazones may all influence the course of diabetic macular oedema. Antagonism of vascular endothelial growth factor offers a new therapeutic avenue that may transform the management of diabetic macular oedema. Several other therapeutic options are under investigation and development, including aminoguanidine, sorbinol, ruboxistaurin and autologous stem cell transfusion.